Dienstag, 27. Juli 2021
Navigation öffnen
Anzeige:
Canakinumab
Canakinumab
 
JOURNAL ONKOLOGIE – STUDIE
BaseTIL

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma

Rekrutierend

NCT-Nummer:
NCT04165967

Studienbeginn:
September 2020

Letztes Update:
29.09.2020

Wirkstoff:
Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2

Indikation (Clinical Trials):
Melanoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 1

Sponsor:
University Hospital, Basel, Switzerland

Collaborator:
GMP network of Basel

Studienleiter

Heinz Läubli, MD PhD
Principal Investigator
Division of Medical Oncology and Cancer Immunology, University Hospital Basel
Alfred Zippelius, Prof.
Study Chair
Division of Medical Oncology and Cancer Immunology, University Hospital Basel

Kontakt

Studienlocations
(1 von 1)

Division of Medical Oncology and Cancer Immunology, University Hospital Basel
4031 Basel
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Heinz Läubli, MD PhD
Phone: +41 61 265 5074
E-Mail: heinz.laeubli@usb.ch

Frank Stenner, Prof.
Phone: +41 61 265 5074
E-Mail: frank.stenner@usb.ch
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Adoptive cell therapy has been previously shown to be an effective treatment option for patients with melanoma. Due to an immunosuppressive microenvironment, not all patients respond to this therapy. In this trial, the immune suppressive microenvironment will be targeted by adding a PD-1 blocking antibody in combination with a TIL Transfer. Tumor-infiltrating lymphocytes will be expanded from resected melanoma samples from the patient and expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Histologically confirmed unresectable or metastatic melanoma

- At least 1 PD-1 targeted immunotherapy and BRAF inhibition in case of BRAF mutated melanoma

- Resectable tumor mass and measurable disease by CT or MRI per RECIST 1.1 criteria (in addition to the resected lesion)

- World Health Organization (WHO) clinical performance Status (ECOG) 0-1

- Adequate organ function

- Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for five months after receiving the last dose of nivolumab for women and seven months for men

- Patients must be able to understand and sign the Informed consent document

- Hematology: Absolute neutrophil count greater than 1.5 x 109/L without support of filgrastim. Platelet count greater than 100 x 109/L. Hemoglobin greater than 5 mmol/L, or 80 g/L.

- Chemistry: Serum alanine aminotransferase (ALAT)/ aspartate transaminase (ASAT) less than 3 times the upper limit of normal, unless patients have liver metastases (< 5 times ULN). Serum creatinine clearance 50 ml/min or higher. Total Bilirubin less than or equal to 20 micromol/L, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 50 micromol/L. Lactate dehydrogenase (LDH) ≤ 2x ULN

- Serology: Seronegative for HIV antibody. Seronegative for hepatitis B antigen, and hepatitis C antibody. Seronegative for syphilis.

Exclusion Criteria:

- Life expectancy of less than three months

- Patients with metastatic ocular/ mucosal or other non-cutaneous melanoma.

- Requirement for immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to randomization

- Uncontrolled central nervous system (CNS) metastases. Controlled CNS metastases must be for at least 4 weeks stable.

- Documented Forced expiratory volume at one second (FEV1) less than or equal to 50% predicted for patients with:

- A prolonged history of cigarette smoking (greater than 20 pack/year within the past 2 years)

- Symptoms of respiratory distress

- All patients' toxicities due to prior non-systemic treatment must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures or focal palliative radiotherapy (to non-target lesions) within the past 4 weeks, as long as all toxicities have recovered to grade 1 or less.

- Women who are pregnant or breastfeeding, because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

- Any active systemic infections, coagulation disorders or other active major medical illnesses.

- Contraindication for IL-2 or nivolumab (allergies etc.).

- Any autoimmune disease: patients with a documented history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease are excluded from this study as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, autoimmune thyroiditis (e.g. Hashimoto's disease), autoimmune hepatitis, systemic progressive sclerosis (scleroderma), Systemic Lupus Erythematosus, autoimmune vasculitis (e.g., Wegener's Granulomatosis). Subjects with motor neuropathy considered of autoimmune origin (e.g., Guillain-Barré Syndrome) are excluded from this study. Patients with vitiligo are eligible to enter the study

Studien-Rationale

Primary outcome:

1. Number of Adverse Events (Time Frame - First 3 months during treatment):
Number of Adverse Events to analyze safety of the combination of TIL transfer with IL-2 therapy

2. Change in body temperature (Degree Celsius) (Time Frame - at each treatment visit (Day 0, and for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing)):
Change in Vital signs ( body temperature) to analyze the safety of the combination of TIL transfer with IL-2 therapy

3. Change in blood pressure (mmHg) (Time Frame - at each treatment visit (Day 0, and for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing)):
Change in Vital signs ( blood pressure) to analyze the safety of the combination of TIL transfer with IL-2 therapy

4. Change in heart beat (beats/minute) (Time Frame - at each treatment visit (Day 0, and for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing)):
Change in Vital signs (heart beat) to analyze the safety of the combination of TIL transfer with IL-2 therapy

5. Change in respiratory frequency (inspiration/minute) (Time Frame - at each treatment visit (Day 0, and for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing)):
Change in Vital signs (respiratory frequency) to analyze the safety of the combination of TIL transfer with IL-2 therapy

6. Change in full blood Counts (number of cells) (Time Frame - at each treatment visit (every 2 weeks) from Day 0= Baseline to week 42):
Change in Laboratory Parameter (full blood counts) to analyze haematological toxicity

Secondary outcome:

1. Overall Response Rate (ORR) fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT scan (Time Frame - First 3 months after TIL administration):
Changes of Tumor volume according to RECIST 1.1

2. Progression Free Survival (PFS) (Time Frame - between pre-treatment and 3-months post-treatment):
Progression free survival, defined as the time between registration to progression or death whichever occurs first.

3. Overall Survival (OS) defined as the time between registration to death due to any cause (Time Frame - 2 years after TIL transfer):
Overall survival will be measured from the beginning of the treatment to the death of the patient or to survival status analysis acquired during the last follow up.

4. Tumor response according to revised Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (Time Frame - between pre-treatment and 3-months post-treatment):
Tumor response according to revised Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

5. Objective response rate (ORR) (Time Frame - 2 years after TIL transfer):
In order to assess the objective response rate CT scans and FDG-PET/CT scans will be performed. Response will be measured by best reduction of tumor volume according to RECIST 1.1

6. Number of Adverse Events according to CTCAE 4.0 (Time Frame - 2 years after TIL transfer):
Overall Safety during whole treatment period analyzed by collection of Adverse Events according to CTCAE 4.0

7. Metabolic Response (Time Frame - during the first 3 months after TIL transfer):
Response measured by 18FDG-uptake

8. Number of Serious Adverse Events according to CTCAE 4.0 (Time Frame - 2 years after TIL transfer):
Overall Safety during whole treatment period analyzed by collection of Serious Adverse Events according to CTCAE 4.0

Geprüfte Regime

  • Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2 (TIL Transfer / anti-PD-1 Therapy Nivolumab / low dose IL-2 / ):
    The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab. Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes. Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2. Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose